Status:
COMPLETED
Vascular Endothelial Growth Factor (VEGF) & LOC387715/HTRA1 Polymorphism in Polypoidal Choroidal Vasculopathy
Lead Sponsor:
Kyungpook National University Hospital
Conditions:
Age-Related Macular Degeneration
Eligibility:
All Genders
60-80 years
Brief Summary
This study is to investigate whether there is an association of the LOC387715/HTRA1 and vascular endothelial growth factor polymorphism with response to treatment with intravitreal ranibizumab injecti...
Detailed Description
This is a retrospective comparative case series comprised of 70 patients being treated for polypoidal choroidal vasculopathy with intravitreal ranibizumab injections and 112 control subjects. Patients...
Eligibility Criteria
Inclusion
- patients older than 60 years of age at onset
- polyp-like terminal aneurysmal dilations with or without branching vascular networks in ICGA and subretinal reddish-orange protrusions corresponding to polyp-like lesions
- patients who had intravitreal injections of 0.5 mg of ranibizumab monthly for 3 months
Exclusion
- patients with retinal or choroidal diseases including pathologic myopia, angioid streaks, idiopathic choroidal neovascularization (CNV), presumed ocular histoplasmosis, and other secondary CNV
- patients who refused genotypic analyses
Key Trial Info
Start Date :
October 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
121 Patients enrolled
Trial Details
Trial ID
NCT01233128
Start Date
October 1 2010
End Date
January 1 2012
Last Update
April 9 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
In Taek Kim
Daegu, Kyungsangpookdo, South Korea, 700-721